Compare AbbVie Inc (ABBV) vs Procter & Gamble Co (PG) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

Procter & Gamble (PG) trades at $149.83, up 0.35% today, with a bullish technical signal from moving averages and ADX indicators. The company maintains strong profitability with a 19.16% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights include a new WNBA partnership and ongoing supply chain improvements, while analyst consensus remains positive with a $159.88 price target.

PG offers stable growth and reliable dividends, supported by consistent cash flow and 69 years of dividend increases. Risks include premium valuation multiples and modest revenue growth outlook. The stock presents a defensive investment opportunity amid market volatility, with upside potential aligned with analyst targets but sensitivity to consumer demand fluctuations.